Brief: Marinus Pharmaceuticals Provides Update On The Phase 3 Raise Trial

Marinus Pharmaceuticals

15/04/2024 13:25

April 15 (Reuters) - Marinus Pharmaceuticals Inc
 MRNS.O :
    * MARINUS PHARMACEUTICALS PROVIDES UPDATE ON THE PHASE 3
RAISE
TRIAL AND REPORTS PRELIMINARY FIRST QUARTER 2024 FINANCIAL
RESULTS
    * MARINUS PHARMACEUTICALS INC: ENROLLMENT IN TRUSTTSC TRIAL
EXPECTED TO COMPLETE MID-MAY WITH TOPLINE DATA ON TRACK FOR
FIRST HALF OF Q4 2024
    * MARINUS PHARMACEUTICALS INC - COST REDUCTION ACTIVITIES TO
EXTEND CASH RUNWAY ARE UNDER REVIEW AND EXPECTED TO BE
IMPLEMENTED Q2 2024
    * MARINUS PHARMACEUTICALS INC - TRIAL DID NOT MEET
PRE-DEFINED
STOPPING CRITERIA AT INTERIM ANALYSIS
    * MARINUS PHARMACEUTICALS INC - COMPLETED RAISE ENROLLMENT
AT
APPROXIMATELY 100 PATIENTS WITH TOPLINE RESULTS EXPECTED SUMMER
2024
    * MARINUS PHARMACEUTICALS INC - FUTURE DEVELOPMENT OF IV
GANAXOLONE IN REFRACTORY STATUS EPILEPTICUS TO BE ASSESSED
FOLLOWING REVIEW OF FINAL RAISE RESULTS
    * MARINUS PHARMACEUTICALS INC SEES PRELIMINARY UNAUDITED NET
PRODUCT REVENUE OF BETWEEN $7.4 AND $7.6 MILLION FOR Q1 OF 2024
    * MARINUS PHARMACEUTICALS INC - PRELIMINARY UNAUDITED CASH,
CASH
EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $113.3 MILLION AS OF
MARCH 31, 2024

Source text for Eikon:  ID:nBw93LJ4Va 
Further company coverage:  MRNS.O